Company intelligence / Profile preview

Gilboa & Licht

Rehovot, Israel

Ownership: Private
Development stage: Other

Overview

Preclinical data presented at AACR 2024 demonstrates SolidT engineered T cells co-administered with therapeutic antibodies show profound anti-tumor activity, tumor eradication in animal models, immune memory formation, and improved safety over CAR-T by targeting high antigen tumor cells while sparing normal tissue.

Therapeutic areas: Oncology
Modalities: T cell therapy
Industry: Biotech

Beyond the preview

Go deeper on Gilboa & Licht.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gilboa & Licht.

Explore the full profile